<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400866</url>
  </required_header>
  <id_info>
    <org_study_id>KSWOG 15-01</org_study_id>
    <nct_id>NCT02400866</nct_id>
  </id_info>
  <brief_title>A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean South West Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean South West Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This aim of study is to evaluate the safety and efficacy of olanzapine for the prevention of
      chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic
      chemotherapy by a randomized, double-blind, placebo-controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate for the acute phase (0-24 hours) after chemotherapy</measure>
    <time_frame>during 24 hours after first cycle of moderately emetogenic chemotherapy (MEC)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate for the delayed phase (24-120 hours) and overall phase (0-120 hours) after chemotherapy</measure>
    <time_frame>during 0-120 hours after first cycle of MEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>no vomiting for the overall phase</measure>
    <time_frame>during 0-120 hours after first cycle of MEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>significant emesis for the overall phase</measure>
    <time_frame>during 0-120 hours after first cycle of MEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>numbers and time for rescue medicaions</measure>
    <time_frame>during 0-120 hours after first cycle of MEC</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects on quality of life by FLIE questionnaire</measure>
    <time_frame>during 0-120 hours after first cycle of MEC</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>palonosetron + dexamethasone + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>palonosetron + dexamethasone + olanzapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 19 years of age

          -  no history of receiving moderately or highly emetogenic chemotherapy during last 6
             months, and is to receive a first course of MEC including one or more of following
             agents: Carboplatin, Cyclophosphamide ≤ 1,500 mg/m2, Daunorubicin, Doxorubicin &lt; 60
             mg/m2, Epirubicin ≤ 90 mg/m2, Irinotecan, Oxaliplatin, Melphalan, Methotrexate ≥ 250
             mg/m2

          -  ECOG performance status 0-2

          -  predicted life expectancy ≥ 3 months

          -  adequate bone marrow, kidney, and liver functionas evidenced by: ANC ≥ 1,500/mm3,
             platelet count ≥ 100,000/mm3, total bilirubine ≤ 2 x ULN, AST ≤ 3 x ULN, ALT ≤ 3 x ULN
             (for subjects with known liver metastases, total bilirubin ≤ 3 x ULN, AST ≤ 5 x ULN,
             ALT ≤ 5 x ULN), Creatinine ≤ 1.5 x ULN or Ccr ≥ 50 ml/min

          -  no episodes of nausea and vomiting during last 24 hours before enrollment

          -  subjects provides written informed consent

        Exclusion criteria:

          -  subjects with uncontrolled neuro-psychiatric disease (alcohol abuse, seizure,
             psychosis etc) except malignant tumor

          -  subject is scheduled to receive highly emetogenic chemotherapeutic agents: Doxorubicin
             or Epirubicin + cyclophosphamide, Cisplatin ≥ 50 mg/m2, Carmustine &gt; 250 mg/m2,
             Cisplatin ≥ 50 mg/m2, Cyclophosphamide &gt; 1,500 mg/m2, Dacarbazine, Doxurubicine ≥ 60
             mg/m2, Epirubicine &gt; 90 mg/m2, Ifosfamide ≥ 2 g/m2 per dose, Mechlorethamine,
             Streptozocin

          -  contraindication to the administration of palonosetron, dexamethasone, and olanzapine
             due to hypersensitivity or any other reasons

          -  subject has severe cognitive impairment

          -  subjects has symptomatic or uncontrolled brain metastasis or brain tumor

          -  female subjects of childbearing potential who dose not agree to use a proper
             contraceptive methods or to limit breast feeding

          -  subject has taken the following agents: risperidone, quetiapine, clozapine,
             phenothiazine, butyrophenone, 5-HT3 antagonist, bezamides, domperidone, cannabinoids,
             NK1 antagonist, bezodiazepines

          -  subject has a plan to receive other chemotherapy, abdomial radiation, surgery, or
             immunotherapy

          -  any history of arrhythmia, uncontrolled congestive heart failure, acute myocardial
             infarction durting last 6 months

          -  history of uncontrolled diabetes

          -  subject who has used any investigational drugs within 30 days of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jooyoung Lee</last_name>
    <phone>82-42-280-7399</phone>
    <email>poppoya99@naver.com</email>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean South West Oncology Group</investigator_affiliation>
    <investigator_full_name>Hwan Jung Yun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cancer patients receiving moderately emetogenic chemotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

